natgillin/translations-raw huggingface dataset:
recombining said polynucleotide of a) at its C-terminal end with polynucleotides encoding from N-to C-terminal a transmembrane domain and at least one, in particular two intracellular signalling domain(s) suitable for providing stimulatory signal(s) to a cell, in particular to a T cell, more particularly a human T cell, expressing the recombinant molecule obtained in b) in a cell, especially in a T cell, more particularly a human T cell, selecting the produced chimeric antigen receptor for its properties after contacting the same with a cell expressing human CD127. 
-rekombiniranja navedenog polinukleotida a) na njegovom C-terminalnom kraju s polinukleotidima koji kodiraju od N- do C-terminalno transmembransku domenu i najmanje jednu, naročito dvije unutarstanične so HR P20191445 T1 signalne domene pogodne za osiguravanje stimulatornog signala (jedne ili više) stanica, naročito T stanica, naročito humanoj T stanici, c. = ekspresije rekombinantne molekule dobivene u b) u stanici, naročito u T stanici, naročito humanoj T stanici, d. = selekcije proizvedenog himernog receptora antigena za njegove osobine poslije njegovog dovođenja u kontakt sa ćelijom koja eksprimira humani CD127.
In a further embodiment, there is provided a macrocyclic sanglifehrin analogue according to formula (I) in solid crystalline form. 
Spoj prema patentnom zahtjevu 1, naznačen time da je u krutom kristalnom obliku.
The composition of claim 10 wherein component (f) comprises one or more organically modified clays. 
Kompozicija prema patentnom zahtjevu 8 ili 9 naznačena time što komponenta (f) sadrži jednu ili više organski modificiranih glina.
11 illustrates one embodiment of a mug-type container 1100 . 
Slika 11 prikazuje jedno ostvarenje posude tipa šalice 1100.
The reaction was worked up by diluting the reaction solution in 30mL EtOAc and washing with water then brine. 
Reakcijska smjesa je bila dorađena razrjeđivanjem reakcijske otopine u 30 mL EtOAc i isprana s vodom i tada sa slanom vodom.
In one aspect of the present invention, the GPR119 agonist is an agonist of human GPR119. DPP-IV Inhibitors 
Pripravak u skladu sa zahtjevom 1, naznačen time, da GPR119 agonist je agonist humanog GPR119.
A composition for use according to claim 1 for increasing an initial period of undisturbed sleep and/or reducing nocturnal voids in a female patient above 65 years of age, the composition comprising an orodispersible dose of desmopressin of 25 µg composition, wherein the dose is measured as the free base of desmopressin. 
Pripravak koji sadrži dezmopresin za uporabu u liječenju nokturije ili noćne poliurije za povećanje početnog razdoblja nesmetanog spavanja kod muškog pacijenta, naznačen time da pripravak sadrži orodisperzibilnu dozu od 50 mikrograma dezmopresina pri čemu se doza mjeri kao slobodna baza dezmopresina i koja se daje pacijentu prije spavanja.
The method of claim 1, wherein the solution is filtered to remove insoluble solid impurities before adding the thiocyanate salt into the solution in step b. 
Postupak prema bilo kojem od zahtjeva 1-9, naznačen time da se otopina prije dodavanja tiocijanatne soli filtrira radi uklanjanja netopljivih krutih nečistoća. 11.
A process for preparing a crystalline form (Form A) of N-(3-cyano-4-methyl-1 H -indol-7-yl)-3-cyanobenzenesulfonamide hydrate according to any one of claims 17 to 22, characterized in that a crystalline form (Form C) of N-(3-cyano-4-methyl-1 H -indol-7-yl)-3-cyanobenzenesulfonamide is recrystallized from a mixed solvent of ethanol and water. 
Postupak za pripravu kristalnog oblika (Oblik A) spoja N-(3-cijano-4-metil-1H-indol-7-il)-3-cijanobenzen-sulfonamid hidrata u skladu s bilo kojim patentnim zahtjevom 17 do 22, naznačen time, da se kristalni oblik (Oblik C) spoja N-(3-cijano-4-metil-1H-indol-7-il)-3-cijanobenzen-sulfonamida rekristalizira iz miješanog otapala etanola i vode.
each carrier comprises a first engage member (14) and a second engage member (15) engaging the first face and a third engage member (16) engaging the second face, 
- svaki nosač sadrži prvi zahvatni član (14) 1 drugi zahvatni član (15) koji zahvaćaju prvu površinu 1 treći zahvatni član (16) koji zahvaća drugu površinu,
A compound of formula (I): 
Spoj formule (I): gdje:
The following Examples illustrate the invention: all temperatures are in °C:- 
Slijedeći primjeri ilustriraju izum: sve temperature su u "C:
Protein AI216611_P0 (SEQ ID NO:43) according to the present invention has an amino acid sequence as encoded by transcript AI216611_T0 (SEQ ID NO:41). 
Pripravak prema zahtjevu 1, naznačen time da navedeni polipeptid sadrži sekvencu amino kiseline iz SEQ ID NO: 147, SEQ ID NO:148 ili SEQ ID NO:299.
Systems and methods of performing gain control 
SUSTAVI I POSTUPCI ZA KONTROLU POJAČANJA
According to the invention, the first end of the insertion tube comprises at least one frame slot for receiving the frame of the intrauterine system. 
Aplikator za umetanje prema zahtjevu 1, naznačen time što prvi kraj klipa (2) obuhvaća ležište za primanje intrauterinog sustava.
and R8 are the same or different and each represent a hydrogen atom, a C1-6 alkyl group, a C3-8 cycloalkyl group, an aryl group, or a heterocyclic group, wherein the C1-6 alkyl group, the C3-8 cycloalkyl group, the aryl group and the heterocyclic group may be substituted with 1 to 4 substituents which are the same or different and are selected from the group of substituents, Rc, to be shown below, 
R' i Rž su isti ili različiti i svaki predstavljaju vodikov atom, skupinu C,g4 alkil, skupinu C3.g cikloalkil, arilnu skupinu, ili heterocikličku skupinu, pri čemu skupina Cig alkil, skupina C3.g cikloalkil, arilna skupina i heterociklička skupina mogu biti supstituirane s 1 do 4 supstituenata koji su isti ili različiti i odabrani su iz skupine supstituenata, R", koji će biti prikazani niže,
The lug causes the cap to be attached to the strap (3) and thus the rest of the inhaler. 
Jezičac uzrokuje da se zatvarač poveže s vrpcom (3) i time s ostatkom inhalatora.
The process according to claim 1, wherein the R functional group(s) of the hydrophobically modified polyalkyleneimine are selected from the group consisting of linear or branched fatty amides or amines, cyclic amides or amines, and mixture thereof. The process according to claim 1, wherein the R functional group(s) of the hydrophobically modified polyalkyleneimine is a linear or branched fatty amide, a cyclic amide or a mixture thereof. 
Proces prema bilo kojem od zahtjeva 1 do 12, naznačen time što se R funkcionalna skupina(e) tog hidrofobno modificiranog polialkilenimin izabire iz grupe koja obuhvaća linearne ili razgranate masne amide ili amine, cikličke amide ili amine, i njihove mješavine, i poželjnije je to linearni ili razgranati masni amid, ciklički amid ili njihove mješavine.
The residue was chromatographed on silica gel (25% to 50% ethyl acteate: cyclohexane) to give the title compound (2.87 g, 84%) as a yellow oil which was a mixture of diastereomers. 
Ostatak se kromatografira na silikagelu (25 % do 50 % etil-acetat/cikloheksan) kako bi se dobilo naslovni spoj (2,87 g, 84 %) u obliku žutog ulja, koje je smjesa dijastereomera,
0 A composition suitable for leather tanning comprising zeolite treated with monocarboxylic acid. The composition of claim 1 characterized in that said monocarboxylic acid is selected from the group of formic acid, acetic acid, propionic acid, glycolic acid, lactic acid or mixtures thereof, preferably from formic acid or acetic acid, most preferably the monocarboxylic acid is formic acid. 
Pripravak prikladan za štavljenje kože i dobiven postupkom prema bilo kojem od zahtjeva 1-3 u obliku praškaste obrađen koncentriranom monokarboksilnom kiselinom izabranom iz grupe koju čine mravlja kiselina, octena kiselina, propionska kiselina, glikolna kiselina, mliječna kiselma i njihove smjese, koncentracija te monokarboksilne kiseline veća je od 84% težinski, i struktura zeolita je intaktna.
a CDRL1 sequence that corresponds to amino acid residues 24 to 34 (KASESVGSFVS) of SEQ ID NO: 36, wherein one, two or three of these amino acid residues is optionally a different amino acid; 
(iv) CDRLI sekvencu koja odgovara aminokiselinskim ostacima 24 do 34 (KASESVGSFEVS) iz SEK ID BR:
The pharmaceutical formulation according to any one of the preceding claims, in which the amphiphilic matrix is selected from the group containing: polar lipids, ceramides, glycolyalkyl ethers, macrogol glycerides, hydroxystearate polyethylene glycols, triglycerides of the C8-C10 fraction of coconut oil, polysorbates, phosphatides, hydrogenated castor oil, esters of monooleate glycerol, linoleics, oily unsaturated polyglycosylated glycerides, capril-caproil, monolaurate polyethylene glycols and their mixtures. 
Farmaceutska formulacija u skladu s bilo kojim od prethodnih patentnih zahtjeva, naznačena time što se amfifilni matriks bira iz skupine koju čine: polarni lipidi, ceramidi, glikol-alkil-eteri, makrogolni gliceridi, polietilen-glikolni hidroksistearati, trigliceridi Cg-C1o frakcije kokosovog ulja, polisorbati, fosfatidi, hidrogenirano ricinusovo ulje, esteri glicerol-monooleata, linoleici, poliglikosilirani gliceridi nezasićenih ulja, kapril-kaproil, monolaurati polietilen-glikola i njihove smjese.
reducing the compound according to formula (16), or salt thereof, to obtain a compound according to formula (1), or salt thereof, wherein in formulae (14) to (16) R1 is hydrogen or a nitrogen protecting group, as defined above. 
gdje R1 je vodikova ili dušikova zaštitna skupina i R4 je CO-aktivacijska skupina; b) reakcija spoja prema formuli (4) ili njegove soli, s bifenilnim spojem, kako bi se dobio spoj u skladu sa sljedećom formulom (5) ili njegova sol: pa i, o
The compound according to claim 1 or 2 which is characterized by a Raman spectroscopic pattern with peaks at values of 3051 cm-1, 3029 cm-1, 3011 cm-1, 2888 cm-1, 824 cm-1 and 717 cm-1. 
Spoj prema Zahtjevu 1 ili 2, naznačen time, da ima uzorak Ramanove spektroskopije s vršnim vrijednostima od 3051 cm", 3029 cm", 3011 cm", 2888 cm"', 824 cm! i 717 cm".
The compound or salt of claim 74 wherein said inflammatory disease is an inflammatory disease of the eye. 
Spoj ili sol za upotrebu prema patentnom zahtjevu 23, naznačen time da je navedeni tumor tumor dojke.
is an alkyl of 1 to 18 carbon atoms, alkenyl of 2 to 18 carbon atoms, or alkynyl of 2 to 18 carbon atoms; 
je alkil sa 1 do 18 atoma ugljika, alkenil sa 2 do 18 atoma ugljika, ili alkinil sa 2 do 18 atoma ugljika;
This provides the possibility of opening and closing the packaging like a book with an angle of more than 180°, preferably 240°, which is essential in order to be packed in automated packing machines, which require that the two sides of the packaging must be opened like a book within an angle of more than 180°, preferably 240°. 
To osigurava mogućnost otvaranja i zatvaranja pakiranja kao knjige pod kutom koji je veći od 180", poželjno 240%, što je važno da bi se obavilo pakiranje u automatiziranim strojevima za pakiranje i što zahtjeva da dvije strane pakiranja moraju biti otvorene kao knjiga pod kutom koji je veći od 180", poželjno 240".
A method according to Claim 1 or 2 comprising step (c), wherein step (c) is carried out before the beginning of the main culture. 
Postupak prema patentnom zahtjevu 2 ili 3, naznačen time što postupak sadrži barem korak (a) i korak (c), i pri čemu se korak (c) provodi prije dodavanja medija sjemenske kulture.
The construct for the use of claim 7, wherein 5µg per square meter patient body surface area are to be administered at the first day(s) of the infusion period, followed by administration of 30µg or 45 µg per square meter patient body surface area as daily dose for the remaining period. 
Konstrukt namijenjen upotrebi u skladu s patentnim zahtjevom 4, naznačen time što 5 µg/m2 površine pacijentovog tijela treba primijeniti prvog odnosno prvih dana perioda infuzije, za čim slijedi primjena 30 µg ili 45 µg/m2 površine pacijentovog tijela kao dnevna doza kroz preostali period.
A monoclonal antibody that binds to the polypeptide of claim 2; binds to human sclerostin with a dissociation constant of less than or equal to 1 x 10-9 M as determined by surface plasmon resonance; and increases at least one of bone formation, bone mineral density, bone mineral content, bone mass, bone quality and bone strength in a mammal. 
Monoklonsko protutijelo koje se veže za polipeptid iz patentnog zahtjeva 2, naznačen time, da se veže za humani sklerostin s disocijacijskom konstantom manjom ili jednakom od 1 x 10% M kako je izmjereno površinskom plazmonskom rezonancijom; te povećava barem jednu formaciju kosti, mineralnu gustoću kosti, mineralni sastav kosti, koštanu masu, kvalitetu kosti i jačinu kosti kod sisavca.
the compound of formula (XIII) is subjected to the action of triphosgene and the isocyanate corresponding to the compound of formula (XIII) is obtained, which is condensed with an amine of formula RaNH2, Ra being as defined in Claim 1, in order to obtain the urea of formula (XIV): 
spoj s formulom (XIII) se podvrgava djelovanju trifosgena i dobiven je izocijanat koji odgovara spoju s formulom (XIII), koji se kondenzira sa aminom s formulom RaNH2, te je Ra kako je definirano u zahtjevu 1, kako bi se dobila urea s formulom (XIV): [image]
Killing of cells and/or inhibition of one or more activities of cells, in particular cell proliferation, by the antibody of the invention is preferably induced by binding of the antibody to GT468 expressed by said cells and/or being associated with the cell surface of said cells. 
ID BR: 2 eksprimiranog od strane spomenutih stanica i/ili vezanog sa površinom spomenutih stanica, poželjno vezivanjem spomenutog antitijela za izvanstanični domen proteina koji sadrži aminokiselinsku sekvencu sa SEK ID BR: 2 eksprimiranog od strane spomenutih stanica i/ili vezanog sa površinom spomenutih stanica.
A PSD95 inhibitor for use according to any one of claims 1 to 11, wherein the reperfusion therapy is performed after determining the subject qualifies for reperfusion based on lack of a completed infarction, an ischemic penumbra and lack of hemorrhage as shown by CT, MRI or PET analysis or wherein the reperfusion therapy is performed at least 12 or at least 24 hours after onset of ischemia or, wherein the reperfusion therapy is performed 275-690 minutes after onset of ischemia. 
Inhibitor PSD-95, namijenjen upotrebi u skladu s bilo kojim od patentnih zahtjeva 1 do 7, naznačen time što se reperfuzijsku terapiju provodi najmanje 12 ili najmanje 24 sata nakon početka ishemije, 1li što se reperfuzijsku terapiju provodi 275-690 minuta nakon početka ishemije.
The compound for the use of claim 8, wherein NHE has a structure of Formula (IV): or a stereoisomer, prodrug or pharmaceutically acceptable salt thereof, wherein: 
Spoj za uporabu u liječenju hiperfosfatemije kod subjekta, pri čemu se odgovarajuća doza spoja daje subjektu i pri čemu je spoj ili njegova farmaceutski prihvatljiva sol.
It is advantageous to apply the mixtures according to the invention post emergent when the crop has in general 1 to 6 leaves. 
Pogodno je primjenjivati smjese prema izumu poslije nicanja kada kulture imaju uglavnom 1 do 6 listova. HR P20080642 T3
If the combination to discourage and prevent abuse of the dosage form according to the invention comprises component (d), it may comprise at least one emetic, which is preferably present in a spatially separated arrangement from the other components of the dosage form according to the invention and, when correctly used, is intended not to exert its effect in the body. 
Ukoliko kombinacija za sprečavanje i osiguravanje oblika davanja prema izumu protiv zlouporabe obuhvaća komponentu (d), ona može imati barem jedan emetik, koji bi prvenstveno trebao biti prisutan tako da je prostorno odijeljen od ostalih komponenata oblika davanja prema izumu i kod propisane primjene ne bi u tijelu trebao razviti bilo kakvo djelovanje.
Figure 1 firstly shows an arrangement 1, which is a nozzle arrangement here and which is separated into groups, consisting of a lower plate-shaped part 2 and of a part 3 which is also plate-shaped and which is disposed on the lower part 2 and is fixedly joined thereto. 
Slika 1 prikazuje najprije napravu 1, koja je ovdje naprava s mlaznicom i koja je odvojena u skupine, koja se sastoji od donjeg pločastog dijela 2 i od dijela 3 koji je također pločast i koji se nalazi na donjem dijelu 2 i s njim je čvrsto spojen.
The bottom extrusion ridge 10 of the inside front wall 7 forms a storage space for matches 9 . 
Donji udubljeni rub 10 unutarnjeg prednjeg zida 7 formira spremišni prostor za šibice 9.
R2′ is a group having the structure: 
R* je skupina sa strukturom:
with a compound of formula VI wherein Q is a hydroxyl or a halide. 
IV sa spojem formule VI: gdje Q predstavlja neki hidroksil ili neki halid.
The oligomeric compound according to claim 1, wherein the third region comprises a non-nucleotide moiety selected from a sterol and a carbohydrate. 
Oligomerni spoj prema bilo kojem od patentnih zahtjeva 1 do 11, naznačen time, da treća regija obuhvaća ne-nukleotidnu aktivnu tvar poput skupine konjugata kao što je sterol, primjerice kolesterol, ili ugljikohidrat poput klastera GalNac/GalNac.
The term “resin”, as used herein, relates to any matrix or carrier material used in a chromatographic column, such as e.g. agarose, sepharose, superose, dextran, sephadex, polypropylene, or the like, that may be derivatized with ligands, or functional groups, such as DEAE, CM, MEP, phenyl, for example, as explained in detail in the “Background of the Invention”. 
Pojam «nosač» na način na koji se ovdje koristi, odnosi se na bilo koji matriks ili materijal nosača koji se koristi kao punjenje u kolonama poput agaroze, sefaroze, superoze, dekstrana, sefadeksa, polipropilena i si., a koji može biti derivatiziran s ligandima ili funkcionalnim skupinama poput DEAE, CM, MEP, fenila, ili na primjer kao što je objašnjeno u detaljima u poglavlju Â«Pozadina izuma».
The coating composition of claim 8, wherein the polyfunctional resin is an alkyd, polyester, polyacrylate, polymethacrylate, phenolic or amino resin. 
Sastav premaza prema zahtjevu 8, naznačen time, da polifunkcionalna smola je alkilna, poliesterska, poliakrilatna, polimetakrilatna, fenolna ili amino smola.
A process according to claim 10, wherein abiraterone acetate is crystallized from a hexane and ethanol solution. 
Postupak u skladu s patentnim zahtjevom 10, naznačen time što abirateron-acetat se kristalitira iz heksanske i etanolne otopine.
An in vitro cell containing the double stranded RNAi agent of claim 1. 
In vitro stanica naznačena time da sadrži dvolančano RNA1 sredstvo prema zahtjevu 1.
The compound 1-{[(2S,3S,4S)-3-ethyl-4-fluoro-5-oxopyrrolidin-2-yl]methoxy}-7-methoxyisoquinoline-6-carboxamide; or a pharmaceutically acceptable salt of said compound or a tautomer of said compound or salt. 
Spoj, naznačen time što je 1-([(2S,3S,4S)-3-etil-4-fluor-5-oksopirolidin-2-il]metoksi)-7-metoksiizokinolin-6- karboksamid; ili farmaceutski prihvatljiva sol navedenog spoja ili tautomer navedenog spoja ili soli.
A method according to claim 53 or 54, wherein the cancer is selected from breast cancer, colon cancer, prostate cancer, lung cancer, gastric cancer, ovarian cancer, endometrial cancer, renal cancer, hepatocellular carcinoma, thyroid cancer, uterine cancer, esophageal cancer, squamous cell carcinoma, leukemia, osteosarcoma, melanoma, glioblastoma and neuroblastoma. 
Lijek, spoj ili njegova sol, ili kristal istog, ili farmaceutska kompozicija za upotrebu prema patentnom zahtjevu 32, gdje je rak odabran od raka dojke, raka debelog crijeva, raka prostate, raka pluća, raka želuca, raka jajnika, raka endometrija, raka bubrega, hepatocelularnog karcinoma, raka tiroide, raka maternice, raka ezofagusa, karcinoma skvamoznih stanica, leukemije, osteosarkoma, melanoma, glioblastoma, neuroblastoma i raka gušterače.
A method for producing mixed OBs of the baculovirus variant SeUS2-A of the Spodoptera exigua multiple nucleopolyhedrovirus (SeMNPV) and the variant SfNIC-C of Spodoptera frugiperda multiple nucleopolyhedrovirus (SfMNPV), characterized by the co-infection of both baculoviruses in fourth instar Spodoptera exigua larvae, and subsequent insect rearing until evident disease or death by polyhedrosis. 
Postupak proizvodnje miješanih OB varijante SeUS2-A bakulovirusa višestrukog nukleopoliedrovirusa koji napada Spodoptera exigua (SeMNPV) 1 varijante SfNIC-C višestrukog nukleopoliedrovirusa koji napada Spodoptera frugiperda (SEMNPV), naznačen time što se provodi suinfekciju s oba bakulovirusa u četvrtom ličinačkom stadiju Spodoptera exigua, uz naknadni uzgoj kukca do pojave bolesti ili smrti od poliedroze.
The process according to claim 12, further comprising removing the t-butoxycarbonyl group of compound 5 to obtain a compound of formula (I), or a pharmaceutically acceptable salt thereof: 
i Spoj formule (I), ili njegov tautomer, mezomer, racemat, enantiomer, dijastereomer i smjesa, i njegova farmaceutski prihvatljiva sol odabrana iz skupine koju čine:
Aspects of the present disclosure include: 
Datum objave europske prijave patenta:
In another embodiment, C is a pyrazole ring. 
C je pirazol-prsten ili imidazol-prsten;
The compound for use according to claim 1, wherein the compound is defined by a and c being a single bond, b being a double bond, and R2 being OR5, OR5 being as defined in claim 1. 
Spoj za uporabu prema zahtjevu 1, gdje je spoj definiran time što su a i c jednostruka veza, b je dvostruka veza.
The implantable drug delivery device of claim 2, wherein the thermoplastic polyurethane comprises macrodiols, diisocyanates, difunctional chain extenders, or mixtures thereof. 
Uređaj za oslobađanje lijeka prema patentnom zahtjevu 16, naznačen time što se termoplastični poliuretan sastoji od makrodiola, diizocijanata, difunkcionalnih produživača lanaca ili njihovih smjesa.
The intrauterine system has the same parts as in FIGS. 
Aplikator prilagođen za umetanje intrauterinog sustava, obuhvaća
at least one sensor, said at least one sensor being adapted to measure a physical parameter, relatable to a lying position used by a user; and 
barem jedan senzor (31; 31'; 31"), pri čemu je navedeni senzor (senzori) prilagođen za mjerenje fizičkog parametra koji je povezan s ležećim položajem koji koristi korisnik;
Amine salt of formula XII wherein R1 is benzyl, R3' is Boc and X is the anion of methanesulfonic acid. 
' naznačena time, da R' je benzil, R* je Boc, a X je anion metansulfonske kiseline.
A composition according to claim 1, which comprises as component (A) the compound 3-difluoromethyl-1-methyl-1H-pyrazole-4-carboxylic acid (9-dichloromethylidenebenzonorbornene-5-yl)amide and as component (B) bixafen. 
Pripravak prema zahtjevu 1, naznačen time da sadrži kao komponentu (A) spoj 3-difluorometil-1-metil-1H-pirazol-4-karboksilna kiselina (9-diklorometiliden-benzonorbornen-5-il)amid, a kao komponentu (B) biksafen.
cooling to 20-25° C. of the mass obtained in step b) in the presence of stirring at the rate of 60-120 rpm, followed by further stirring of the mass at 20-25° C. for a time ranging from 2 to 12 hours; slow addition to the suspension obtained in c) of a solvent selected from the group consisting of acetone, ethanol and methanol, followed by cooling of the resulting suspension at a temperature ranging from 3° C. to 7° C.; 
C) hlađenje do 20-25"C mase dobivene u koraku b) uz miješanje pri brzini od 60-120 rpm, zatim daljnje miješanje mase pri 20-25*C u rasponu vremena od 2 do 12 sati; d) polagano dodavanje u suspenziju dobivenu u c) otapala koje je odabrano iz skupine koju čine aceton, etanol ili metanol, preferirano aceton, zatim hlađenje dobivene suspenzije pri temperaturi u rasponu od 3"C do TC;
A first process comprises reacting a cobalt compound, preferably cobalt hydroxide, with a carboxylic acid functional polymer having a mean molecular weight of more than 2000. 
- reakcija spoja kobalta, poželjno kobaltova hidroksida, s funkcionalnim polimerom karboksilne kiseline koji ima prosječnu molekulsku masu veću od 2000;
A beacon as claimed in claim 1, wherein said casing is in the form of a parallelepiped-shaped plate. 
Baliza prema patentnom zahtjevu 1, naznačena time, da je navedeno kućište u obliku paralelopipedno oblikovane ploče.